Table 3. Keratinocyte Carcinoma HRs Associated With TCI Exposure Compared With Topical Corticosteroid Exposure vs Unexposure.
| Variable | HR (95% CI) | |
|---|---|---|
| TCI vs topical corticosteroid | TCI vs unexposed | |
| Keratinocyte carcinoma | ||
| Unadjusted | 0.91 (0.83-1.00) | 0.93 (0.84-1.04) |
| Model 1a | 1.15 (1.05-1.27) | 1.19 (1.07-1.32) |
| Model 2b | 1.02 (0.93-1.13) | 1.03 (0.92-1.14) |
| Basal cell carcinoma | ||
| Unadjusted | 0.90 (0.80-1.01) | 0.93 (0.82-1.06) |
| Model 1a | 1.11 (0.99-1.25) | 1.16 (1.03-1.32) |
| Model 2b | 1.01 (0.90-1.14) | 1.04 (0.91-1.19) |
| Squamous cell carcinoma | ||
| Unadjusted | 0.86 (0.75-0.99) | 0.91 (0.78-1.06) |
| Model 1a | 1.13 (0.99-1.30) | 1.17 (1.00-1.36) |
| Model 2b | 0.94 (0.82-1.08) | 0.91 (0.78-1.06) |
Abbreviations: HR, hazard ratio; TCI, topical calcineurin inhibitor.
a
Adjusted for age, sex, race/ethnicity, and calendar year.
b
Adjusted for variables in model 1 and number of annual dermatology visits, prior keratinocyte carcinoma history, immunosuppression (assessed 2 years before study entry and during follow-up), exposed to systemic atopic dermatitis treatment (assessed 2 years before study entry and during follow-up), autoimmune disease (assessed during follow-up), UV treatment (assessed during follow-up), chemotherapy (assessed during follow-up), radiotherapy (assessed during follow-up), and previous topical corticosteroid treatment (before cohort entry).